FDA’s Proposed Guidance for Laboratory Developed Tests: How Should Regulators Balance the Risks and Promise of Innovation in Clinical Genetics?

Ítems similars

• The FDA’s New Guidance for Off-Label Promotion Is Only a Start
  per: Field, Robert I.
  Publicat: (2008)
• FDA guidance for next generation sequencing-based testing: balancing regulation and innovation in precision medicine
  per: Luh, Frank, et al.
  Publicat: (2018)
• FDA’s commitment to transparency
  per: Guharoy, Roy, et al.
  Publicat: (2021)
• Pharmacists Welcome FDA’s Opioids REMS: How Directly Will They Be Affected?
  per: Barlas, Stephen
  Publicat: (2012)
• OpenFDA: an innovative platform providing access to a wealth of FDA’s publicly available data
  per: Kass-Hout, Taha A, et al.
  Publicat: (2016)